{"id":47818,"date":"2014-12-04T20:46:53","date_gmt":"2014-12-05T01:46:53","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/duke-signs-exclusive-licensing-agreement-with-leading-genome-editing-company\/"},"modified":"2014-12-04T20:46:53","modified_gmt":"2014-12-05T01:46:53","slug":"duke-signs-exclusive-licensing-agreement-with-leading-genome-editing-company","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/genetic-engineering\/duke-signs-exclusive-licensing-agreement-with-leading-genome-editing-company\/","title":{"rendered":"Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company"},"content":{"rendered":"<p><p>    Duke University has signed an     exclusive licensing agreement with Editas Medicine, a    leading genome editing company, for genetic engineering    technologies developed in the lab of Charles    Gersbach, assistant professor of biomedical engineering.    The agreement focuses on Gersbachs work with genome    engineering technologies known as CRISPR\/Cas9 and TALENs.  <\/p>\n<p>      Charles Gersbach    <\/p>\n<p>    The agreement allows broad use of the technology developed in    Gersbachs lab for the prevention or treatment of human    disease. To this point, Gersbachs most notable     work in that field is on Duchenne muscular dystrophy, a    genetic disease affecting one in 3,500 newborn males that    currently has no approved treatment and causes muscular    deterioration, paralysis and eventual death, usually by age 25.    Gersbachs work is focused on using gene editing to correct the    mutated gene that causes the disease, in contrast to treating    the resulting symptoms of the disease. Gersbach has also    pioneered the use of both     CRISPR\/Cas9 and     TALEs for turning on genes in a way that could be used to    treat degenerative disorders or compensate for genetic defects.  <\/p>\n<p>    Charlies deep expertise in both genome editing and in this    area of biology is a tremendous asset as we begin to understand    how to apply genome editing technologies to specific diseases,    said Katrine Bosley, chief executive officer of Editas    Medicine. Gersbach is also serving as a scientific advisor to    Editas.  <\/p>\n<p>    Editas is a leading genome editing company and part of a    transformational new area of healthcaregenomic medicine. The    company was founded by the pioneers and world leaders in genome    editing bringing specific expertise in CRISPR\/Cas9 and TALENs    technologies. The companys mission is to translate its    proprietary technology into novel solutions to treat a broad    range of genetically-driven diseases.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View original post here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.pratt.duke.edu\/news\/duke-signs-exclusive-licensing-agreement-leading-genome-editing-company\/RK=0\/RS=y4XqMulwIAfmeFelwhlUvH10DLI-\" title=\"Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company\">Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Duke University has signed an exclusive licensing agreement with Editas Medicine, a leading genome editing company, for genetic engineering technologies developed in the lab of Charles Gersbach, assistant professor of biomedical engineering.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/genetic-engineering\/duke-signs-exclusive-licensing-agreement-with-leading-genome-editing-company\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-47818","post","type-post","status-publish","format-standard","hentry","category-genetic-engineering"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/47818"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=47818"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/47818\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=47818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=47818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=47818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}